Research programme: regenerative cell therapy - MandalMed

Drug Profile

Research programme: regenerative cell therapy - MandalMed

Latest Information Update: 02 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MandalMed
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cell replacements; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Brain injuries; Spinal cord injuries

Highest Development Phases

  • Research Brain injuries; Spinal cord injuries

Most Recent Events

  • 02 Aug 2016 Early research is ongoing in USA
  • 02 Aug 2016 Research programme: regenerative cell therapy - MandalMed is available for licensing as of 02 Aug 2016. http://www.mandalmed.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top